Pharmafile Logo
Pharmafocus logo
Advanced Search

PMCPA

Showing 6 posts of 81 posts found.

Outdated HRT website breaches Code

September 22, 2010
Medical Communications ABPI, Code of Practice, PMCPA, Pfizer, Wyeth

A website which contained outdated information about the risk of using hormone replacement therapy has been found in breach of …

News

Plans for greater transparency with KOLs

August 6, 2010
Medical Communications ABPI, BMA, Code of Practice, KOL, MHRA, PMCPA

Pharmaceutical companies in the UK will have to declare the amount of money paid to its healthcare professionals who act …

News

Astellas Pharma censured over advisory boards

July 9, 2010
Medical Communications, Sales and Marketing Astellas, Code of Practice, PMCPA

Astellas has been the subject of ‘naming and shaming’ advertisements in three medical journals after advisory board meetings it ran …

News
Blog footer

Digital Pharma: No breakthrough, but UK’s digital issues out in the open

May 14, 2010
Medical Communications Code of Practice, PMCPA, digi, digital, pm society

The UK’s Code of Practice regulator will produce guidance for pharma on digital marketing, but is reluctant to make formal …

Feature

Solvay reprimanded for cheques to GPs

April 7, 2010
Sales and Marketing Code of Practice, PMCPA, Solvay

Three UK pharma companies have been ‘named and shamed’ for serious breaches of the ABPI’s Code of Practice. Solvay, Pfizer …

News

Ferring and Stiefel named and shamed for Code breaches

January 12, 2010
Medical Communications ABPI, Code of Practice, Ferring, PMCPA, Stiefel

Ferring Pharmaceuticals and Stiefel Laboratories have been named and shamed for breaching the ABPI Code of Practice. Adverts giving details …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026